PDF(Pubmed)
Abstract：
BACKGROUND: Challenges remain in determining the most effective treatment strategies and identifying patients who would benefit from adjuvant or neoadjuvant therapy in renal cell carcinoma. The objective of this review is to provide a comprehensive overview of biomarkers in metastatic renal cell carcinoma (mRCC) and their utility in prediction of treatment response, prognosis, and therapeutic monitoring in patients receiving systemic therapy for metastatic disease.
METHODS: A systematic literature search was conducted using the PubMed database for relevant studies published between January 2017 and December 2022. The search focused on biomarkers associated with mRCC and their relationship to immune checkpoint inhibitors, targeted therapy, and VEGF inhibitors in the adjuvant, neoadjuvant, and metastatic settings.
RESULTS: The review identified various biomarkers with predictive, prognostic, and therapeutic monitoring potential in mRCC. The review also discussed the challenges associated with anti-angiogenic and immune-checkpoint monotherapy trials and highlighted the need for personalized therapy based on molecular signatures.
CONCLUSIONS: This comprehensive review provides valuable insights into the landscape of biomarkers in mRCC and their potential applications in prediction of treatment response, prognosis, and therapeutic monitoring. The findings underscore the importance of incorporating biomarker assessment into clinical practice to guide treatment decisions and improve patient outcomes in mRCC.
METHODS: A systematic literature search was conducted using the PubMed database for relevant studies published between January 2017 and December 2022. The search focused on biomarkers associated with mRCC and their relationship to immune checkpoint inhibitors, targeted therapy, and VEGF inhibitors in the adjuvant, neoadjuvant, and metastatic settings.
RESULTS: The review identified various biomarkers with predictive, prognostic, and therapeutic monitoring potential in mRCC. The review also discussed the challenges associated with anti-angiogenic and immune-checkpoint monotherapy trials and highlighted the need for personalized therapy based on molecular signatures.
CONCLUSIONS: This comprehensive review provides valuable insights into the landscape of biomarkers in mRCC and their potential applications in prediction of treatment response, prognosis, and therapeutic monitoring. The findings underscore the importance of incorporating biomarker assessment into clinical practice to guide treatment decisions and improve patient outcomes in mRCC.
摘要：
背景：在确定最有效的治疗策略和确定将受益于肾细胞癌辅助或新辅助治疗的患者方面仍然存在挑战。这篇综述的目的是全面概述转移性肾细胞癌（mRCC）中的生物标志物及其在预测治疗反应中的应用。预后,以及接受转移性疾病全身治疗的患者的治疗监测。
方法：使用PubMed数据库对2017年1月至2022年12月发表的相关研究进行了系统的文献检索。搜索的重点是与mRCC相关的生物标志物及其与免疫检查点抑制剂的关系。靶向治疗,和佐剂中的VEGF抑制剂，新辅助,和转移设置。
结果：评论确定了各种具有预测性，预后，和mRCC的治疗监测潜力。该综述还讨论了与抗血管生成和免疫检查点单一疗法试验相关的挑战，并强调了基于分子特征的个性化治疗的必要性。
结论：这篇全面的综述为mRCC中生物标志物的景观及其在预测治疗反应中的潜在应用提供了有价值的见解，预后,和治疗监测。研究结果强调了将生物标志物评估纳入临床实践以指导治疗决策和改善mRCC患者预后的重要性。
方法：使用PubMed数据库对2017年1月至2022年12月发表的相关研究进行了系统的文献检索。搜索的重点是与mRCC相关的生物标志物及其与免疫检查点抑制剂的关系。靶向治疗,和佐剂中的VEGF抑制剂，新辅助,和转移设置。
结果：评论确定了各种具有预测性，预后，和mRCC的治疗监测潜力。该综述还讨论了与抗血管生成和免疫检查点单一疗法试验相关的挑战，并强调了基于分子特征的个性化治疗的必要性。
结论：这篇全面的综述为mRCC中生物标志物的景观及其在预测治疗反应中的潜在应用提供了有价值的见解，预后,和治疗监测。研究结果强调了将生物标志物评估纳入临床实践以指导治疗决策和改善mRCC患者预后的重要性。
